The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Tumor shrinkage and overall survival (OS) from multicenter phase II study of modified FOLFOX7 (combination chemotherapy of infusional 5-FU/l-leucovorin and intermittent oxaliplatin) with bevacizumab in the first-line therapy of colorectal cancer: CRAFT trial.
Keiji Koda
No relevant relationships to disclose
Hideyuki Ishida
No relevant relationships to disclose
Ryoji Katoh
No relevant relationships to disclose
Kotaro Maeda
No relevant relationships to disclose
Toru Tezuka
No relevant relationships to disclose
Hideyuki Mishima
No relevant relationships to disclose
Naohiro Tomita
No relevant relationships to disclose
Norio Saito
No relevant relationships to disclose
Chikuma Hamada
No relevant relationships to disclose
Junichi Sakamoto
No relevant relationships to disclose